Cabaletta Bio, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2019. Although the request references 2019 Q4, this filing is an annual Form 10-K rather than a quarterly Form 10-Q. The filing was dated March 30, 2020.
Business Context and Reporting Period
Cabaletta Bio is a clinical-stage biotechnology company developing engineered CAAR T-cell therapies intended to selectively eliminate pathogenic B cells involved in autoimmune and alloimmune diseases while preserving normal B-cell function. The company operates as a single reportable segment and has not generated product revenue.
- Lead candidate: DSG3-CAART for mucosal pemphigus vulgaris.
- Additional programs: DSG3/1-CAART for mucocutaneous pemphigus vulgaris, MuSK-CAART for MuSK myasthenia gravis, and FVIII-CAART for Hemophilia A patients with Factor VIII alloantibodies.
- The FDA cleared the DSG3-CAART IND in September 2019. The company planned to begin the DesCAARTes Phase 1 trial in 2020.
- DSG3-CAART received FDA orphan drug designation for pemphigus vulgaris in January 2020.
- The company had 22 employees as of December 31, 2019, including 21 full-time employees.
Financial Metrics
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $11.7 million | $4.5 million | +$7.2 million |
| General and administrative expense | $7.0 million | $1.7 million | +$5.3 million |
| Total operating expenses | $18.7 million | $6.2 million | +$12.5 million |
| Loss from operations | $(18.7) million | $(6.2) million | Higher operating loss |
| Interest income | $1.7 million | $0.2 million | +$1.5 million |
| Net loss | $(16.9) million | $(12.2) million | Loss increased $4.7 million |
| Net loss attributable to common stockholders | $(22.3) million | $(12.2) million | Includes $5.3 million deemed dividend |
| Basic and diluted loss per share | $(4.07) | $(6.87) | Not directly comparable due to recapitalization and IPO |
| Cash and cash equivalents | $136.2 million | $33.0 million | +$103.2 million |
| Accumulated deficit | $33.0 million | $12.5 million | Deficit increased |
Profit margins are not meaningful because the company had no revenue. The 2019 operating loss was primarily driven by increased research and development activity, manufacturing preparation, personnel additions, preclinical development, clinical trial start-up costs and public-company expenses.
Cash Flow, Debt and Liquidity
- Cash used in operating activities was $16.0 million in 2019, compared with $4.7 million in 2018.
- Cash used in investing activities was $0.7 million, primarily for property and equipment.
- Cash provided by financing activities was $119.9 million, including $48.7 million of net proceeds from Series B preferred stock and approximately $71.2 million from the IPO.
- The October 2019 IPO and partial underwriter over-allotment generated approximately $71.0 million of net proceeds in total.
- The company had no convertible notes outstanding at December 31, 2019 and reported no credit facility or committed debt financing.
- Management stated that cash and cash equivalents were expected to fund operations through at least the third quarter of 2022, based on the current operating plan and assumptions that could prove incorrect.
- The company expects to require substantial additional financing to complete clinical development, expand manufacturing capabilities and support operations.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased 161%, reflecting higher personnel costs, manufacturing of clinical and preclinical supplies, development services and initial clinical trial activities.
- General and administrative expense increased approximately 306%, primarily due to additional personnel, professional services, rent, insurance and costs associated with becoming a public company.
- Net loss increased from $12.2 million to $16.9 million, despite higher interest income and the absence of the $6.2 million convertible-note fair-value expense recorded in 2018.
- Operating cash burn increased substantially as the company advanced DSG3-CAART toward clinical testing.
- Cash and stockholders’ equity improved materially following the Series B financing and IPO. Preferred stock was converted into common stock in connection with the IPO.
- Stock-based compensation increased to $2.3 million from $0.6 million.
Guidance, Outlook, Risks and Unusual Items
Management expects continued and substantial net losses and increasing research and development and general and administrative expenses for the foreseeable future. There is no revenue guidance because product candidates remain in early clinical or preclinical development and no product has been approved for commercial sale.
- The initial Phase 1 DSG3-CAART study was expected to be open-label, dose-escalating and focused primarily on safety and tolerability. The company planned to administer treatment without lymphodepleting preconditioning initially.
- Major development risks include cytokine release syndrome, neurotoxicity, off-target tissue recognition, inadequate target engagement, product rejection, manufacturing variability and insufficient clinical efficacy.
- The company relies substantially on Penn and affiliated entities for research, clinical, regulatory and manufacturing services. The Services Agreement is generally scheduled to expire no earlier than October 2021, subject to completion of contracted services and termination rights.
- Manufacturing remains dependent on Penn, CHOP and future contract development and manufacturing organizations. Technology transfer, comparability and commercial-scale production remain unresolved execution risks.
- The amended and restated Penn/CHOP license includes annual research funding obligations, milestone payments that could approach $20.0 million across multiple products, low-single-digit royalties on net sales and sublicense income obligations.
- The company identified COVID-19 as a potential source of clinical trial, manufacturing, supply chain, staffing and financing disruption. The filing does not provide a quantified financial impact.
- A 2019 phishing incident resulted in unauthorized access to certain employee email accounts. The company stated that the incident did not materially affect its business or financial condition.
- As of December 31, 2019, the company was not party to legal proceedings expected to have a material adverse impact.
- The company had federal, state and local net operating loss carryforwards of approximately $17.5 million, $19.2 million and $10.1 million, respectively, subject to potential limitations under tax law.
Most Important Facts for Investors to Verify
- Whether the DesCAARTes Phase 1 trial was initiated on schedule and whether enrollment, dosing and safety data met management’s expectations.
- Current cash balance, quarterly cash burn and the updated date by which management expects additional financing to be required.
- Clinical evidence of DSG3-CAART target engagement, tolerability, cytokine release syndrome, neurotoxicity and clinical response.
- Progress toward IND submissions for DSG3/1-CAART, MuSK-CAART and FVIII-CAART.
- Manufacturing capacity, product comparability and the timing and cost of transitioning away from Penn-dependent manufacturing.
- Any changes to the Penn and CHOP license, sponsored research obligations, milestone exposure, royalties or termination rights.
- Potential dilution from future equity offerings, stock options, the employee stock purchase plan and conversion of non-voting common stock.
- Whether the cash runway remains consistent with management’s estimate of funding operations through at least the third quarter of 2022.